Alm, you make some excellent points that need to be hammered home:
1) "A big scale pharma company can make money out of vascepa"
2) "Amarin can not" -
3) "The present board and present plans will leave company profit less and cash reducing for several years to come"
4) "Denner I feel want this done in 12 months - he has been in it for nearly a year already"
All of those are self-explanatory and quite clear. As far as #4, you are quite correct that his first purchases of Amarin stock were a year ago, and I am surprised that not much has changed with Amarin. I would think Denner has been trying quietly and patiently to whisper in management's ear, but I think enough time has passed and he now is going to take a more direct approach. We all have to hope that he succeeds and doesn't throw in the towel..
And as far as a valuation for a BO, Amarin has to realize that it cannot expect a value based on what BP can do with V.
News 
Market Data 
Discover 
